 FLORHAM PARK, N.J., Dec. 09, 2020 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021. 